111In-DTPA-dinutuximab-IRDye800CW

N/A

Report date: 2025/01/26 15:36:17

Base Information

Drug Name111In-DTPA-dinutuximab-IRDye800CW
Drug Alias NameDTPA [Indium-111]-dinutuximab-IRDye800CW
ClassificationRadiation-emitting productsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionDisialoganglioside GD2 inhibitors
TargetsDisialoganglioside GD2
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pittsburgh
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pittsburgh
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A